DexCom Given Buy Rating at Wedbush (DXCM)
DexCom (NASDAQ:DXCM)‘s stock had its “buy” rating reiterated by stock analysts at Wedbush in a report issued on Monday, Analyst RN reports. They currently have a $31.00 target price on the stock. Wedbush’s price target would indicate a potential upside of 6.75% from the stock’s previous close.
Other equities research analysts have also recently issued reports about the stock. Analysts at Zacks reiterated a “neutral” rating on shares of DexCom in a research note to investors on Friday, September 27th. They now have a $31.00 price target on the stock. Separately, analysts at JPMorgan Chase & Co. initiated coverage on shares of DexCom in a research note to investors on Friday, September 13th. They set an “overweight” rating and a $32.00 price target on the stock. Finally, analysts at Feltl & Co. raised their price target on shares of DexCom from $16.50 to $18.25 in a research note to investors on Monday, August 12th. They now have a “sell” rating on the stock. Three research analysts have rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company’s stock. DexCom currently has an average rating of “Hold” and an average price target of $22.84.
DexCom (NASDAQ:DXCM) traded up 5.79% on Monday, hitting $29.04. The stock had a trading volume of 699,938 shares. DexCom has a 52-week low of $12.03 and a 52-week high of $29.24. The stock’s 50-day moving average is $27.57 and its 200-day moving average is $22.48. The company’s market cap is $2.073 billion.
DexCom (NASDAQ:DXCM) last released its earnings data on Wednesday, August 7th. The company reported ($0.14) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.16) by $0.02. The company had revenue of $35.80 million for the quarter, compared to the consensus estimate of $31.14 million. During the same quarter in the prior year, the company posted ($0.21) earnings per share. The company’s quarterly revenue was up 53.0% on a year-over-year basis. On average, analysts predict that DexCom will post $-0.53 earnings per share for the current fiscal year.
DexCom, Inc (NASDAQ:DXCM) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.